What do systematic reviews say?

Vasopressin receptor antagonists vs placebo or no treatment

It is very uncertain whether vasopressin receptor antagonists changes death compared with placebo or no treatment (very low certainty).

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  RR 1.11 [0.92, 1.33]
  15 studies · 2330 participants
  Very low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 297 participants
  Very low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 580 participants
  Low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1169 participants
  Low

Vasopressin receptor antagonists vs placebo or no treatment

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  21 studies · 2641 participants
  Moderate

Vasopressin receptor antagonists vs placebo or no treatment

Vasopressin receptor antagonists probably leads to higher serum sodium concentration (response) compared with placebo or no treatment (moderate certainty).

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  RR 2.49 [1.95, 3.18]
  18 studies · 2104 participants
  Moderate

Vasopressin receptor antagonists vs placebo or no treatment

Vasopressin receptor antagonists probably leads to higher rapid sodium increase compared with placebo or no treatment (moderate certainty).

• Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia 2018 · Cochrane Headline outcomes only
  RR 1.67 [1.16, 2.4]
  14 studies · 2058 participants
  Moderate

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.89 [0.45, 1.77]
  1 study · 1023 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in death compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.7 [0.31, 1.55]
  1 study · 1055 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in doubling serum creatinine compared with selective aldosterone antagonist (low certainty).

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  RR 0.8 [0.03, 19.51]
  1 study · 1055 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found